BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) drug resistance is an important threat to the overall success of antiretroviral therapy (ART). Because of the limited sensitivity of commercial assays, transmitted drug resistance (TDR) may be underestimated; thus, the effect that TDR has on treatment outcome needs to be investigated. The objective of this study was to investigate the prevalence of TDR in HIV-infected patients and to evaluate the significance of TDR with respect to treatment outcome by analyzing plasma viral RNA and peripheral blood mononuclear cell proviral DNA for the presence of drug resistance mutations. METHODS: In a prospective study, we investigated the level of TDR in 61 patients by comparing the results of a sensitive multiplex-primer-extension approach (termed HIV-SNaPshot) that is capable of screening for 9 common nucleoside reverse-transcriptase inhibitor and nonnucleotide reverse-transcriptase inhibitor mutations with those of a commercial genotyping kit, ViroSeq (Abbott). RESULTS: Twenty-two patients were found to carry mutations. More patients with TDR were identified by the HIV-SNaPshot assay than by ViroSeq analysis (33% vs 13%; [P=.015). There was no significant difference in the time from initiation of ART to virological suppression between susceptible patients and those carrying low- or high-level resistance mutations (mean +/- standard deviation, 128 +/- 59.1 vs 164.9 +/- 120.4; P=.147). Furthermore, analyses of CD4 cell counts showed no significant difference between these 2 groups 1 year after the initiation of ART (mean, 184 vs 219 cells/microL; P=.267). CONCLUSION: We found the prevalence of TDR in recently infected ART-naive patients to be higher than that estimated by ViroSeq genotyping alone. Follow-up of patients after treatment initiation showed a trend toward there being more clinical complications for patients carrying TDR, although a significant effect on treatment outcome could not be demonstrated. Therefore, the clinical relevance of low-abundance resistant quasispecies in early infection is still in question.
BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) drug resistance is an important threat to the overall success of antiretroviral therapy (ART). Because of the limited sensitivity of commercial assays, transmitted drug resistance (TDR) may be underestimated; thus, the effect that TDR has on treatment outcome needs to be investigated. The objective of this study was to investigate the prevalence of TDR in HIV-infectedpatients and to evaluate the significance of TDR with respect to treatment outcome by analyzing plasma viral RNA and peripheral blood mononuclear cell proviral DNA for the presence of drug resistance mutations. METHODS: In a prospective study, we investigated the level of TDR in 61 patients by comparing the results of a sensitive multiplex-primer-extension approach (termed HIV-SNaPshot) that is capable of screening for 9 common nucleoside reverse-transcriptase inhibitor and nonnucleotide reverse-transcriptase inhibitor mutations with those of a commercial genotyping kit, ViroSeq (Abbott). RESULTS: Twenty-two patients were found to carry mutations. More patients with TDR were identified by the HIV-SNaPshot assay than by ViroSeq analysis (33% vs 13%; [P=.015). There was no significant difference in the time from initiation of ART to virological suppression between susceptible patients and those carrying low- or high-level resistance mutations (mean +/- standard deviation, 128 +/- 59.1 vs 164.9 +/- 120.4; P=.147). Furthermore, analyses of CD4 cell counts showed no significant difference between these 2 groups 1 year after the initiation of ART (mean, 184 vs 219 cells/microL; P=.267). CONCLUSION: We found the prevalence of TDR in recently infected ART-naive patients to be higher than that estimated by ViroSeq genotyping alone. Follow-up of patients after treatment initiation showed a trend toward there being more clinical complications for patients carrying TDR, although a significant effect on treatment outcome could not be demonstrated. Therefore, the clinical relevance of low-abundance resistant quasispecies in early infection is still in question.
Authors: Sara Gianella; Wayne Delport; Mary E Pacold; Jason A Young; Jun Yong Choi; Susan J Little; Douglas D Richman; Sergei L Kosakovsky Pond; Davey M Smith Journal: J Virol Date: 2011-06-01 Impact factor: 5.103
Authors: Jaime Soria; Marta Bull; Caroline Mitchell; Alberto La Rosa; Sandra Dross; Kelli Kraft; Robert Coombs; Eduardo Ticona; Lisa Frenkel Journal: AIDS Res Hum Retroviruses Date: 2011-08-05 Impact factor: 2.205
Authors: Jessica R Keys; Shuntai Zhou; Jeffrey A Anderson; Joseph J Eron; Lauren A Rackoff; Cassandra Jabara; Ronald Swanstrom Journal: AIDS Res Hum Retroviruses Date: 2015-04-02 Impact factor: 2.205
Authors: Jonathan Z Li; Roger Paredes; Heather J Ribaudo; Michael J Kozal; Evguenia S Svarovskaia; Jeffrey A Johnson; Anna Maria Geretti; Karin J Metzner; Martin R Jakobsen; Katherine Huppler Hullsiek; Lars Ostergaard; Michael D Miller; Daniel R Kuritzkes Journal: J Infect Dis Date: 2012-12-21 Impact factor: 5.226
Authors: Valerie F Boltz; Yajing Bao; Shahin Lockman; Elias K Halvas; Mary F Kearney; James A McIntyre; Robert T Schooley; Michael D Hughes; John M Coffin; John W Mellors Journal: J Infect Dis Date: 2014-01-16 Impact factor: 5.226
Authors: Valerie F Boltz; Wei Shao; Michael J Bale; Elias K Halvas; Brian Luke; James A McIntyre; Robert T Schooley; Shahin Lockman; Judith S Currier; Fred Sawe; Evelyn Hogg; Michael D Hughes; Mary F Kearney; John M Coffin; John W Mellors Journal: JCI Insight Date: 2019-10-03
Authors: Max Lataillade; Jennifer Chiarella; Rong Yang; Steven Schnittman; Victoria Wirtz; Jonathan Uy; Daniel Seekins; Mark Krystal; Marco Mancini; Donnie McGrath; Birgitte Simen; Michael Egholm; Michael Kozal Journal: PLoS One Date: 2010-06-03 Impact factor: 3.240